Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases
There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer. Evolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outc...
Saved in:
| Published in: | The Journal of urology Vol. 207; no. 2; p. 302 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.02.2022
|
| Subjects: | |
| ISSN: | 1527-3792, 1527-3792 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer.
Evolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outcomes included recurrence-free survival (RFS) and overall survival (OS). Associations were assessed using univariable and multivariable models.
In all, 70.9% of cases underwent open RC in the last decade, although trend for robot-assisted RC rose since 2009. While lymphadenectomy template remained consistent, nodal submission changed to anatomical packets in 2002 with increase in yield (p <0.001). Neoadjuvant chemotherapy (NAC) use increased with time with concomitant decrease in adjuvant chemotherapy; this was notable in the last decade (p <0.001) and coincided with improved pT0N0M0 rate (p=0.013). Median 5-year RFS and OS probabilities were 65% and 55%, respectively. Advanced stage, NAC, delay to RC, lymphovascular invasion and positive margins were associated with worse RFS (all, multivariable p <0.001). RFS remained stable over time (p=0.73) but OS improved (5-year probability, 1990-1999 51%, 2010-2018 62%; p=0.019). Among patients with extravesical and/or node-positive disease, those who received NAC had worse outcomes than those who directly underwent RC (p ≤0.001).
Despite perioperative and surgical advances, and improved pT0N0M0 rates, there has been no overall change in RFS trend following RC, although OS rates have improved. While patients who are downstaged with NAC derive great benefit, our real-world experience highlights the importance of preemptively identifying NAC nonresponders who may have worse post-RC outcomes. |
|---|---|
| AbstractList | There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer.
Evolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outcomes included recurrence-free survival (RFS) and overall survival (OS). Associations were assessed using univariable and multivariable models.
In all, 70.9% of cases underwent open RC in the last decade, although trend for robot-assisted RC rose since 2009. While lymphadenectomy template remained consistent, nodal submission changed to anatomical packets in 2002 with increase in yield (p <0.001). Neoadjuvant chemotherapy (NAC) use increased with time with concomitant decrease in adjuvant chemotherapy; this was notable in the last decade (p <0.001) and coincided with improved pT0N0M0 rate (p=0.013). Median 5-year RFS and OS probabilities were 65% and 55%, respectively. Advanced stage, NAC, delay to RC, lymphovascular invasion and positive margins were associated with worse RFS (all, multivariable p <0.001). RFS remained stable over time (p=0.73) but OS improved (5-year probability, 1990-1999 51%, 2010-2018 62%; p=0.019). Among patients with extravesical and/or node-positive disease, those who received NAC had worse outcomes than those who directly underwent RC (p ≤0.001).
Despite perioperative and surgical advances, and improved pT0N0M0 rates, there has been no overall change in RFS trend following RC, although OS rates have improved. While patients who are downstaged with NAC derive great benefit, our real-world experience highlights the importance of preemptively identifying NAC nonresponders who may have worse post-RC outcomes. There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer.PURPOSEThere are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer.Evolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outcomes included recurrence-free survival (RFS) and overall survival (OS). Associations were assessed using univariable and multivariable models.MATERIALS AND METHODSEvolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outcomes included recurrence-free survival (RFS) and overall survival (OS). Associations were assessed using univariable and multivariable models.In all, 70.9% of cases underwent open RC in the last decade, although trend for robot-assisted RC rose since 2009. While lymphadenectomy template remained consistent, nodal submission changed to anatomical packets in 2002 with increase in yield (p <0.001). Neoadjuvant chemotherapy (NAC) use increased with time with concomitant decrease in adjuvant chemotherapy; this was notable in the last decade (p <0.001) and coincided with improved pT0N0M0 rate (p=0.013). Median 5-year RFS and OS probabilities were 65% and 55%, respectively. Advanced stage, NAC, delay to RC, lymphovascular invasion and positive margins were associated with worse RFS (all, multivariable p <0.001). RFS remained stable over time (p=0.73) but OS improved (5-year probability, 1990-1999 51%, 2010-2018 62%; p=0.019). Among patients with extravesical and/or node-positive disease, those who received NAC had worse outcomes than those who directly underwent RC (p ≤0.001).RESULTSIn all, 70.9% of cases underwent open RC in the last decade, although trend for robot-assisted RC rose since 2009. While lymphadenectomy template remained consistent, nodal submission changed to anatomical packets in 2002 with increase in yield (p <0.001). Neoadjuvant chemotherapy (NAC) use increased with time with concomitant decrease in adjuvant chemotherapy; this was notable in the last decade (p <0.001) and coincided with improved pT0N0M0 rate (p=0.013). Median 5-year RFS and OS probabilities were 65% and 55%, respectively. Advanced stage, NAC, delay to RC, lymphovascular invasion and positive margins were associated with worse RFS (all, multivariable p <0.001). RFS remained stable over time (p=0.73) but OS improved (5-year probability, 1990-1999 51%, 2010-2018 62%; p=0.019). Among patients with extravesical and/or node-positive disease, those who received NAC had worse outcomes than those who directly underwent RC (p ≤0.001).Despite perioperative and surgical advances, and improved pT0N0M0 rates, there has been no overall change in RFS trend following RC, although OS rates have improved. While patients who are downstaged with NAC derive great benefit, our real-world experience highlights the importance of preemptively identifying NAC nonresponders who may have worse post-RC outcomes.CONCLUSIONSDespite perioperative and surgical advances, and improved pT0N0M0 rates, there has been no overall change in RFS trend following RC, although OS rates have improved. While patients who are downstaged with NAC derive great benefit, our real-world experience highlights the importance of preemptively identifying NAC nonresponders who may have worse post-RC outcomes. |
| Author | Mitra, Anirban P Djaladat, Hooman Miranda, Gus Quinn, David I Schuckman, Anne K Cai, Jie Daneshmand, Siamak Bhanvadia, Sumeet |
| Author_xml | – sequence: 1 givenname: Anirban P orcidid: 0000-0002-6549-5943 surname: Mitra fullname: Mitra, Anirban P organization: Currently at Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas – sequence: 2 givenname: Jie surname: Cai fullname: Cai, Jie organization: Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California – sequence: 3 givenname: Gus surname: Miranda fullname: Miranda, Gus organization: Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California – sequence: 4 givenname: Sumeet surname: Bhanvadia fullname: Bhanvadia, Sumeet organization: Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California – sequence: 5 givenname: David I surname: Quinn fullname: Quinn, David I organization: Division of Cancer Medicine and Blood Diseases, Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California – sequence: 6 givenname: Anne K surname: Schuckman fullname: Schuckman, Anne K organization: Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California – sequence: 7 givenname: Hooman surname: Djaladat fullname: Djaladat, Hooman organization: Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California – sequence: 8 givenname: Siamak surname: Daneshmand fullname: Daneshmand, Siamak organization: Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34994657$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtuFDEQRS0URB7kC5CQlyyY4Ge7mx2MhpcSJSLp9ajarhmMuu2J7Y6Yv-PT8IhESm2qdO-to1KdkqMQAxLyhrMLzjrz4Ud_wZ6VEEq8ICdcC7OQphNHz-Zjcprzb8a40ka8IsdSdZ1qtDkhf68gwBYnDIXeJQwuUwiOXs_FxgkzjRt6A8VXO9M-OEzb6MOW_gTnLYx0uc8FbYnTnm5ion2K5ReO_uBAsj7ECQ6IKtLPI7i6_5GuHuI4Fx_Dk9MH_4Ap-7I_KLdxrmIKlTD6Cg0e6OrPDlM9wiKNNUrle6lMDWTMr8nLDYwZzx_7Gem_rO6W3xaX11-_Lz9dLqzmnViAHlrTWKNQbrQUTgjUsu3Q2gGHQQmlVes4Z5ZLaw0A6pbJ1gEbGB8arcUZefefu0vxfsZc1pPPFscRAsY5r0XDWyF1w5oaffsYnYcJ3XqX_ARpv376uvgHxJqJZQ |
| CitedBy_id | crossref_primary_10_1016_j_urolonc_2023_09_007 crossref_primary_10_1007_s00345_024_05248_y crossref_primary_10_1016_j_clgc_2023_05_019 crossref_primary_10_1097_JU_0000000000003146 crossref_primary_10_1016_j_ajur_2024_12_007 crossref_primary_10_1016_j_clgc_2024_102257 crossref_primary_10_1016_j_euf_2024_09_002 crossref_primary_10_24060_2076_3093_2024_14_1_5_12 crossref_primary_10_1111_bju_15954 crossref_primary_10_1245_s10434_024_15858_w crossref_primary_10_1016_j_euf_2023_06_014 crossref_primary_10_3390_cancers17030404 crossref_primary_10_1002_ijc_34690 crossref_primary_10_1016_j_eururo_2023_04_009 crossref_primary_10_1177_17562872241226582 crossref_primary_10_1186_s12894_024_01459_y crossref_primary_10_1016_j_euo_2022_10_003 crossref_primary_10_1016_j_eururo_2023_08_004 crossref_primary_10_1016_j_euf_2022_10_011 crossref_primary_10_2340_sju_v59_24024 crossref_primary_10_1016_j_urolonc_2023_09_017 crossref_primary_10_1111_iju_15377 crossref_primary_10_1016_j_euf_2023_10_008 crossref_primary_10_1016_j_urolonc_2024_10_009 crossref_primary_10_1016_j_urolonc_2023_02_005 crossref_primary_10_3390_jcm13154349 crossref_primary_10_1016_j_urolonc_2023_04_016 crossref_primary_10_1080_14737140_2025_2535657 crossref_primary_10_1111_bju_16215 crossref_primary_10_1016_j_eururo_2022_05_009 crossref_primary_10_1111_bju_16210 crossref_primary_10_3889_oamjms_2022_10845 crossref_primary_10_1038_s41598_025_93674_2 crossref_primary_10_1177_17562872251315302 crossref_primary_10_1177_18758592241296279 crossref_primary_10_1097_MOU_0000000000001016 crossref_primary_10_1016_j_euo_2023_02_008 crossref_primary_10_1002_bco2_190 crossref_primary_10_1038_s41585_023_00842_y crossref_primary_10_1016_j_clgc_2023_12_002 crossref_primary_10_1245_s10434_024_15730_x crossref_primary_10_1097_MOU_0000000000001230 crossref_primary_10_1038_s41585_022_00693_z |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/JU.0000000000002242 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3792 |
| ExternalDocumentID | 34994657 |
| Genre | Journal Article |
| GeographicLocations | California |
| GeographicLocations_xml | – name: California |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: KL2 TR001854 |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABPXF ABVCZ ABWVN ABXYN ABZZY ACGFS ACILI ACLDA ACOAL ACRPL ACVFH ACXJB ACZKN ADCNI ADGGA ADGHP ADHPY ADMUD ADNKB ADNMO ADZCM AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFTRI AFUWQ AGHFR AGQPQ AHOMT AHQNM AHQVU AHRYX AHVBC AI. AIGII AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ AOQMC ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8 ADKSD ADSXY |
| ID | FETCH-LOGICAL-c5192-a5b876c74e3f532d22e5389eccbebb424548d110c13cc7aae58038da0b01b6552 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000740713200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-3792 |
| IngestDate | Mon Sep 08 07:23:19 EDT 2025 Mon Jul 21 06:03:07 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | cystectomy urinary bladder neoplasms neoadjuvant therapy prognosis urinary diversion |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5192-a5b876c74e3f532d22e5389eccbebb424548d110c13cc7aae58038da0b01b6552 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6549-5943 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8746892 |
| PMID | 34994657 |
| PQID | 2618235606 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2618235606 pubmed_primary_34994657 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-February |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-February |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 2022 |
| References | 34994655 - J Urol. 2022 Feb;207(2):312-313 |
| References_xml | – reference: 34994655 - J Urol. 2022 Feb;207(2):312-313 |
| SSID | ssj0014572 |
| Score | 2.5686665 |
| Snippet | There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer.
Evolution of modern bladder cancer management and its... There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer.PURPOSEThere are conflicting reports on outcome trends... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 302 |
| SubjectTerms | Academic Medical Centers - statistics & numerical data Academic Medical Centers - trends Aged California - epidemiology Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - therapy Chemotherapy, Adjuvant - statistics & numerical data Chemotherapy, Adjuvant - trends Cystectomy - methods Cystectomy - statistics & numerical data Cystectomy - trends Disease-Free Survival Female Humans Lymph Node Excision - statistics & numerical data Lymph Node Excision - trends Male Middle Aged Neoadjuvant Therapy - statistics & numerical data Neoadjuvant Therapy - trends Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Prospective Studies Retrospective Studies Robotic Surgical Procedures - statistics & numerical data Robotic Surgical Procedures - trends Urinary Bladder - pathology Urinary Bladder - surgery Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - therapy |
| Title | Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34994657 https://www.proquest.com/docview/2618235606 |
| Volume | 207 |
| WOSCitedRecordID | wos000740713200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEF-0FvGl2i-_yxT6aPDcj-zGF1FRpNTrUTy4t2O_UgRN9HIK_e_80zqzyZGnQsE85GE3yQZmdua3O7PzY-ybLXJlj0yZoasMmeSlzRx61sygrIXHFXQRE2vJDz0cmsmkGHUbbk2XVrmwiclQh9rTHvkhIn3DBfrn_OThMSPWKIqudhQay2xFIJShlC496aMIUiXyJmJuxYlU8EXVoUIffh-3lQu7Cx0Z_zfGTL7mcv21f7nB3nUoE05btXjPlmL1ga1ed3H0j-ylz3qBNisWbBXg59Mch4kN1CWM2oKrDSRmpN81ujj4ZVNUB86p_LOf1_d_ADEvjGd0jOvulnqImqiq7y19Ahvh7I5M2-wYLp47JV_09Ckh1JKo_OKsgv6wGPRlmIESTUEcCKnxgSY2n9j48uLm_CrruBwyjxiRZ1Y5tLteyyhKJXjgPKKpLVCBXHSOwq_SBIQi_kh4r62NygyECZb2aV2uFP_M3lR1FbcYCDeQdhBUULmWylljvdGFUcXASRWc3WZfF7KZ4lyhAIitYv3UTHvpbLPNVsDTh7aox1Tg0k_mSu_8x9u7bI3TKYiUvL3HVkq0FHGfvfXP89tm9iUpId6Ho-u_YBbn4g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Management+Trends+and+Outcomes+of+Patients+Undergoing+Radical+Cystectomy+for+Urothelial+Carcinoma+of+the+Bladder%3A+Evolution+of+the+University+of+Southern+California+Experience+over+3%2C347+Cases&rft.jtitle=The+Journal+of+urology&rft.au=Mitra%2C+Anirban+P&rft.au=Cai%2C+Jie&rft.au=Miranda%2C+Gus&rft.au=Bhanvadia%2C+Sumeet&rft.date=2022-02-01&rft.eissn=1527-3792&rft.volume=207&rft.issue=2&rft.spage=302&rft_id=info:doi/10.1097%2FJU.0000000000002242&rft_id=info%3Apmid%2F34994657&rft_id=info%3Apmid%2F34994657&rft.externalDocID=34994657 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-3792&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-3792&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-3792&client=summon |